FindTrial
Sign In

Test with patients seeking to demonstrate the efficacy and safety of Hycos MG 500 in chronic or acute wounds

Clinical study, single-blind, of the efficacy and safety of the product Hycos MG 500

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-74kf6vm
Enrollment
Unknown
Registered
2024-11-18
Start date
2024-05-30
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pressure Ulcer

Interventions

It is a study aimed at proving the efficacy and safety of the product Hycos Mg 500, a cream solution intended for skin regeneration. The study was conducted in a single group, in a clinical trial, sin
E05.940.790.500

Sponsors

Nipo Serviços Médicos SS Ltda
Lead Sponsor
Instituto de Saúde e Bem Estar da Mulher
Collaborator

Eligibility

Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: The participating patient has a wound, lesion, or bedsore. The injury requires dressings. Age between 18 and 90 years old. Any ethnicity, color/race, and skin phototype. Both genders. Patients are in the early stages of treatment

Exclusion criteria

Exclusion criteria: Pregnancy. Neonates. Sensitivity to the components of the medication

Design outcomes

Primary

MeasureTime frame
Demonstrate the efficacy and safety of Hycos MG 500 I in humans affected by chronic or acute wounds—

Secondary

MeasureTime frame
No secondary outcomes are expected—

Countries

Brazil

Contacts

Public ContactFrederico Viana

TCI Laboratório Biotecnológico Ltda

frederico@tcilab.com.br+55 38 99886-3565

Outcome results

None listed

Source: REBEC (via WHO ICTRP)